Results - Announcements
Bliss GVS Pharma Ltd share price ticked higher by 4.99% to Rs 682.5 after the company's net profit saw a mild growth of 3.83% to Rs 53.34 crore, while revenue from operations slightly gained 9.73% to Rs 313.37 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.44%. It has marginally improved by 5.74% over last one week and crept higher by 0.60% in last one month while the market capitalization of Bliss GVS Pharma Ltd has improved by 8.59% and 46.21% in the same period respectively.
Profit before tax (PBT) of Bliss GVS Pharma Ltd stood at Rs 75.1 crore in Q3 FY26, surging by 84.84% year-on-year, and declining 0.50% quarter-on-quarter. EBITDA came in at Rs 72 crore, jumping 106.42% YoY and rising 8.22% sequentially.
Total expenses went up by 11.03% to Rs 243.28 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 135.82 crore, witnessing a sharp rise of 43.51% YoY, while employee benefits expense was at Rs 44.99 crore, inching up 4.51% YoY.
For the TTM ended FY26, revenue from operations grew 14.50% to Rs 927.11 crore, while net profit soared by 49.27% to Rs 134.73 crore, compared to previous TTM. EBITDA jumped by 9326% to Rs 90.5 crore, and PBT soared 50.90% to Rs 189.59 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 138.72 crore in FY26, as against Rs 105.91 crore in FY25.
Bliss GVS Pharma Ltd surged by 348.57% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.